Halozyme Therapeutics HALO Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's additional paid-in capital?
- Halozyme Therapeutics (HALO) reported additional paid-in capital of $27.39M in Q1 2026.
- How has Halozyme Therapeutics's additional paid-in capital changed year-over-year?
- Halozyme Therapeutics's additional paid-in capital increased by 260.5% year-over-year, from $7.6M to $27.39M.
- What is the long-term trend for Halozyme Therapeutics's additional paid-in capital?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's additional paid-in capital has grown at a -54.6% compound annual growth rate (CAGR), from $625.48M to $12M.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.